Creating Treatment Goals for Psoriasis: A Patient’s Guide

Psoriasis treatment works best when it’s aimed at something specific. Without a clear target, it’s easy to settle for “somewhat better” when genuinely clear skin is realistically within reach.

This is exactly why dermatology has moved toward a structured approach called treat-to-target. This guide explains how these goals are set, what benchmarks doctors actually use, and how to build a treatment plan that reflects your own priorities.

Why Psoriasis Needs Defined Treatment Goals

For years, psoriasis treatment lacked a consistent standard for what “success” actually meant. Without one, both patients and doctors risked settling for partial improvement rather than pushing toward genuinely clear skin.

The desire to give psoriasis patients the best care possible drove the National Psoriasis Foundation’s efforts to establish the first psoriasis treatment targets in the United States. These targets exist precisely to prevent exactly this kind of complacency.

As one member of the NPF Medical Board put it plainly. Having goals that can be objectively measured keeps clinicians from growing complacent, even when they believe they’re already doing their best for patients.

The Treat-to-Target Approach, Explained

Treat-to-target is a structured framework borrowed from the management of other chronic diseases, like diabetes and hypertension. Rather than accepting vague improvement, it sets a specific, measurable goal and a specific time frame to reach it.

Where This Framework Came From

The treatment targets were developed through research, discussion, and consensus-building among NPF Medical Board members, dermatology leaders, practicing dermatologists, and psoriasis patients themselves, and were published by the Journal of the American Academy of Dermatology in November 2016. This wasn’t a single expert’s opinion; it reflected broad agreement across the field.

Why a Target-Based Model Matters for Chronic Disease

The treat-to-target paradigm has been shown to improve outcomes and reduce costs in chronic disease management generally, though it was, until relatively recently, not yet firmly established in psoriasis compared to conditions like rheumatoid arthritis. Bringing this same rigor to psoriasis care was a deliberate, evidence-driven decision.

The Core NPF Treatment Targets

The National Psoriasis Foundation’s targets are built around body surface area (BSA), a measurement covered in more depth in our psoriasis diagnosis guide. These targets give both patients and doctors a shared, concrete number to work toward.

The 3-Month Target

The most preferred time for evaluating patient response after starting a new psoriasis therapy is at 3 months, according to the Delphi consensus process behind these guidelines. This checkpoint is early enough to catch an ineffective treatment quickly, without giving up on a slower-acting therapy prematurely.

After three months on a new treatment, the target is to have psoriasis on 1 percent or less of total body surface area. To put that in perspective, one percent of body surface area is roughly equivalent to the size of one entire hand, including the palm, fingers, and thumb.

The “Acceptable Response” Middle Ground

Not every treatment hits the ideal target on the first checkpoint, and the guidelines account for this directly. An acceptable response at 3 months is either a BSA of 3% or less, or a BSA improvement of 75% or more from baseline.

This middle category gives patients and physicians a reasonable, evidence-based off-ramp. If the acceptable response is met, a patient and their doctor may decide to continue the same treatment for another three months rather than switching right away.

The 6-Month Checkpoint and Ongoing Maintenance

If the target still isn’t met by six months, the guidelines are clear about what should happen next. To reach the treat-to-target goal, NPF recommends changing the dose, adding a new treatment, or switching to a different treatment altogether at each checkpoint where the goal remains unmet.

Once clearance is achieved, the goal shifts from getting better to staying better. During the maintenance period, evaluation every 6 months was the most preferred interval, with a target response of BSA 1% or less at each of those follow-up visits.

Beyond BSA: PASI-Based Treatment Targets

While BSA dominates everyday clinical practice, PASI-based targets are widely used in research and by specialists managing more complex or treatment-resistant cases. These targets have become more ambitious as treatment options have improved.

The Shift Toward PASI 90

Older treatment benchmarks aimed for a 75% improvement in PASI score. That standard has shifted meaningfully upward as newer medications have raised what’s realistically achievable.

The ultimate goal of therapy is full blanching of the skin, and an improvement of 90% or better compared to baseline PASI is now considered treatment success by the European Medicines Agency. Many clinicians now advocate for this more robust 90% improvement target, given the increased efficacy of newer treatments compared to what was available even a decade ago.

Absolute PASI: A More Consistent Standard

Percentage-based improvement has one meaningful limitation: it depends heavily on how severe a person’s psoriasis was to begin with. Absolute PASI scores solve this problem by setting a fixed number regardless of starting point.

Large real-world data sets have helped establish exactly where that fixed number should sit. An absolute PASI of 2 or less was found to be concordant with a 90% PASI improvement in 90% of cases, based on data from over 13,000 patients in the UK’s BADBIR registry.

Current European guidelines define a PASI 75 response as the minimum therapeutic target, while PASI 90 or an absolute PASI below 2 are considered the more desirable goals. This two-tier structure — a floor and an aspiration — mirrors the “acceptable” versus “target” distinction used in the BSA-based NPF framework.

Ideal vs. Realistic Goals

Expert consensus groups have increasingly emphasized the importance of separating an ideal outcome from a realistic one for any individual patient. A panel of experts agreed on the importance of clearly differentiating between ideal and realistic goals when establishing therapeutic targets in moderate to severe psoriasis.

This distinction matters because complete, 100% clearance isn’t achievable, or even necessarily the right goal, for every patient. In one national Delphi consensus process, achieving PASI 100 did not reach expert agreement as a required standard target, while absolute PASI of 3 or less and a 90% or greater improvement were both strongly endorsed as realistic benchmarks.

When Should Treatment Move Beyond Topicals?

One of the most important treatment goal decisions is knowing when mild-disease treatment is no longer the right fit. This threshold isn’t just about how much skin is affected.

The Traditional BSA Threshold

Body surface area remains a helpful starting reference point for this decision. A 10% body surface area threshold often serves as the traditional benchmark for considering systemic therapy, according to dermatologists discussing shared decision-making in psoriasis care.

Why “High-Impact Areas” Change the Calculation

Total body surface area alone can understate how disruptive a smaller patch of psoriasis really is. Systemic treatment is frequently necessary for patients with a lower BSA if their psoriasis affects high-impact areas like the palms, soles, genitals, or hairline, since these locations cause disproportionate physical and emotional burden.

This is where clinical judgment and patient input matter more than a single number. The National Psoriasis Foundation provides support for clinicians to advocate for systemic treatment options when a patient’s quality of life is significantly impaired, regardless of objective coverage scores like BSA alone.

Setting Goals That Reflect What Matters to You

Objective severity scores are only part of the picture. A genuinely well-built treatment plan also reflects what the patient in front of the doctor actually cares about.

What Patients Say They Want

Large surveys have directly asked patients with psoriasis what their treatment goals actually are, and the results go well beyond simple skin clearance. Among patients with psoriatic arthritis, the top three treatment goals were reducing joint pain, lessening fatigue, and reducing joint stiffness, in that order of priority.

Quality of life impact tends to be severe enough to justify this level of attention. In one large patient survey, the mean Dermatology Life Quality Index score was 18.3, with more than 90% of respondents reporting a moderate, very large, or extremely large effect on their life from their psoriasis.

Why Preference, Not Just Severity, Should Guide Treatment

Research increasingly shows that disease severity alone doesn’t predict what a patient wants or needs from treatment. Patients’ preferences are shaped more by how much their condition affects daily life than by objective disease severity, according to a multicenter German study of systemic therapy-naive patients.

This has direct implications for how goals should be set in practice. Discussing patient preferences, such as route of administration and quality-of-life goals, can help dermatologists involve patients in shared decision-making and improve satisfaction and treatment adherence.

What Patients Weigh When Choosing a Treatment

Beyond effectiveness, patients consistently weigh a specific set of practical treatment attributes. Response rate, speed of response, response maintenance, and quality-of-life measures were all identified as being among the top influential treatment attributes across a systematic review of patient preference studies.

Safety concerns and treatment burden factor in just as heavily as effectiveness for many patients. Patients weigh the benefits of a treatment against the risks of side effects and toxicities, and even convenience issues like dosing frequency or route of administration, when choosing between therapeutic options.

Why Shared Decision-Making Improves Outcomes

None of this is simply a matter of patient comfort; it has measurable effects on how well treatment actually works. Low levels of treatment adherence are exacerbated by individual patient beliefs about treatment and low levels of involvement from healthcare professionals in the decision-making process.

The inverse is true as well, and it benefits everyone involved. Increasing patient involvement in prescribing decisions can positively influence adherence rates and treatment satisfaction, which in turn reduces unnecessary costs from ineffective treatment and complications.

Tools Built Specifically for This Conversation

Because patients sometimes struggle to articulate exactly what they want from treatment, researchers have begun building structured tools to guide the conversation itself. The PSO-TARGET grid consists of 12 therapeutic goals distributed across 4 major components commonly used in quality-of-life studies for chronic disease, designed specifically to improve communication between patients and dermatologists.

This kind of tool addresses a documented, real communication gap. Discrepancies between patient and physician treatment goals, combined with the increasing importance of shared decision-making, highlight the need for psoriasis-specific tools that improve this communication rather than relying on quality-of-life instruments built for other conditions.

Building Your Own Treatment Goal Framework

Bringing all of this together, a well-constructed psoriasis treatment plan usually rests on four pillars. None of these replace a conversation with your dermatologist, but they give that conversation real structure.

1. A Clear, Measurable Skin Target

Start with a concrete number, whether that’s the NPF’s 1% BSA target or an absolute PASI score your dermatologist recommends. A total of 1% BSA is roughly equivalent to one of your own palms, including the fingers, making this a number you can track yourself between visits.

2. A Defined Time Frame

Attach a specific checkpoint to that number rather than leaving it open-ended. The 3-month initial assessment, followed by 6-month maintenance checks described above, gives structure that prevents a plan from drifting indefinitely without reassessment.

3. Quality-of-Life and Personal Priorities

Bring your own priorities into the conversation explicitly, whether that’s joint pain, fatigue, visible areas, treatment convenience, or side-effect tolerance. Health professionals are encouraged to discuss emotional wellbeing and concerns beyond biomedical factors and to offer personalized health education as part of this process.

4. A Plan for What Happens If the Goal Isn’t Met

Decide in advance, together with your doctor, what the next step looks like if a checkpoint isn’t reached. This might mean adjusting a dose, adding a second treatment, or switching therapies entirely, following the same logic used in the formal treat-to-target checkpoints described above.

Special Considerations for Setting Goals

A few situations call for adjusting this general framework rather than applying it uniformly.

Psoriatic Arthritis Changes the Calculation

When joint disease is present alongside skin psoriasis, treatment goals need to expand beyond skin clearance alone. Because psoriatic arthritis can cause permanent joint damage if not treated, a treat-to-target approach could delay or prevent further joint damage and improve quality of life, making joint-specific measures just as important as PASI or BSA.

Difficult-to-Treat Disease

Not every patient reaches the standard target on a first, second, or even third treatment attempt. International dermatology bodies have recognized this reality directly. The International Psoriasis Council and the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis have launched a global consensus initiative specifically to define difficult-to-treat and treatment-refractory psoriasis, aiming to improve consistency in how these more complex cases are managed.

Realistic Goals for Older Patients or Those With Comorbidities

Comorbidities and medication interactions, discussed in our “What Causes Psoriasis?” and pillar guides, can also reasonably shift what an appropriate target looks like. A slightly less aggressive target may be the right, medically sound choice when balanced against a patient’s broader health picture, rather than a sign of undertreatment.

Why These Goals Need Regular Reassessment

Treatment goals are not meant to be set once and forgotten. Life circumstances, disease severity, and even treatment effectiveness itself can shift over time, which is precisely why the maintenance checkpoints described above exist.

Patients should check in with their health care provider every six months once a treatment target has been reached, to make sure the same level of improvement is being maintained. This is not a sign that something has gone wrong; it’s simply a built-in part of how psoriasis is meant to be managed over the long term, echoing the broader theme of ongoing medical monitoring covered throughout our pillar guide. For a full walkthrough of how treatment goals translate into specific medication choices, see our complete guide, “What Is Psoriasis? A Complete Guide to Causes, Symptoms, and Treatment.”

Frequently Asked Questions

Sources and References

1. National Psoriasis Foundation, “Treating to Target” — psoriasis.org/treating-to-target.
2. National Psoriasis Foundation, “Treat to Target” — psoriasis.org/treat-to-target.
3. National Psoriasis Foundation, “Treating to Target FAQ” — psoriasis.org/treating-to-target-faq.
4. National Psoriasis Foundation, “Primary Care & Psoriatic Disease” — psoriasis.org/primary-care-and-psoriatic-disease.
5. National Psoriasis Foundation, “Care Path: Making a Treatment Decision” — psoriasis.org/care-path-treat.
6. Armstrong A.W. et al., “From the Medical Board of the National Psoriasis Foundation: Treatment Targets for Plaque Psoriasis,” Journal of the American Academy of Dermatology, ScienceDirect, 2016.
7. MedCentral, “Psoriasis, Psoriatic Arthritis, and Effective Treat-to-Target,” February 2024.
8. “Treat-to-Target Outcomes With Tapinarof Cream 1% in Phase 3 Trials for Plaque Psoriasis,” PubMed.
9. HMP Global Learning Network, “Psoriasis Severity: More Than Just a Score Card,” The Dermatologist.
10. International Psoriasis Council, “Commentary: Psoriasis Treat to Target: Defining Outcomes in Psoriasis,” April 2023.
11. Mahil S.K. et al., “Psoriasis Treat to Target: Defining Outcomes in Psoriasis Using Data from BADBIR,” PMC.
12. Puig L. et al., “Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo,” Acta Dermato-Venereologica.
13. Mrowietz U. et al., “PASI90 Response: The New Standard in Therapeutic Efficacy for Psoriasis,” PubMed, 2014.
14. “S3 Guideline for the Treatment of Psoriasis Vulgaris, Adapted from EuroGuiDerm — Part 1,” PMC, 2025.
15. “Therapeutic Goals and Treatment Response Evaluation in Moderate to Severe Psoriasis: An Experts Opinion Document,” PMC and PubMed.
16. “Korean Expert Consensus Using the Modified Delphi Method,” Annals of Dermatology.
17. “Long-Term, Durable, Absolute PASI and Health-Related Quality of Life Improvements with Risankizumab Treatment,” PMC.
18. HCPLive, “Patient Preferences and Shared Decision-Making in Psoriasis Care,” April 2026.
19. “The Importance of Understanding Patient and Physician Preferences for Psoriasis Treatment Characteristics: A Systematic Review of Discrete-Choice Experiments,” Taylor & Francis Online.
20. “Understanding Treatment Preferences in Patients with Moderate to Severe Plaque Psoriasis in the USA,” PMC, 2019.
21. “Treatment Preferences Among Systemic Therapy-Naïve Patients with Atopic Dermatitis or Psoriasis in Germany,” Dermatology and Therapy, Springer Nature, December 2025.
22. “Evaluation of Psoriasis Patients’ Attitudes Toward Benefit-Risk and Therapeutic Trade-Offs in Their Choice of Treatments,” PMC.
23. Armstrong A. et al., “Patient-Identified Treatment Goals for Psoriatic Disease: Results From a US Patient Survey,” SAGE Journals, 2025.
24. “The PSO-TARGET Grid: A Shared Decision-Making Tool for Psoriasis,” Dermatology and Therapy, Springer Nature.

This article is intended for general educational purposes and does not replace personalized medical advice. Anyone with psoriasis should work with a board-certified dermatologist to set treatment goals appropriate to their individual health, severity, and priorities.